Sandoz Inc. is on track to get its second biosimilar approval in the US in June 2016 following FDA’s acceptance of its application for a biosimilar to Amgen Inc.’s rheumatoid arthritis and psoriasis drug Enbrel (etanercept).
But it could face a long delay to market unless it gets around Amgen's patents (the last of which expires in 2029) or opts to launch at risk.